
Published today, our reasons for optimism that success rates in drug discovery can be improved by picking the right targets using human genetics: nature.com/articles/s41586-0… I break the key findings down panel by panel in this thread:
Is having even more gene-disease associations still useful for picking drug targets? For which types of programs does it matter? Has pharma shifted focus towards genetically validated targets? New paper by me, @mnelsonxy, @DongCoco90417, & @jivecast doi.org/10.1101/2023.06.23.2…👇











